Stay updated on Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Sign up to get notified when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.

Latest updates to the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page
- Check3 days agoChange DetectedThe website now displays Revision: v3.6.3, replacing the previous Revision: v3.6.2, indicating an update to the page's revision identifier rather than to study data or content.SummaryDifference0.0%

- Check10 days agoChange DetectedAn updated software build identifier (v3.6.2) is now displayed on the page, replacing the previous v3.6.0. This appears to be routine page maintenance and does not modify the study information or visible content.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRecruitment status is updated to No longer looking for participants, reflecting that participant enrollment has ended. The page also adds new user-facing sections (How to Read a Study Record, Common Questions, How to Join a Study), reformats the Intervention/Treatment heading, and lists Revision: v3.6.0 as the current version.SummaryDifference0.3%

- Check32 days agoChange DetectedThe page's revision label was updated to v3.5.5, representing a minor version update to the page. This does not modify the study details or visible content.SummaryDifference0.0%

- Check46 days agoChange DetectedLakefront Biotherapeutics NV has been added to the Collaborators and Investigators section, and Galapagos NV has been removed. This reflects changes in collaboration and may affect attribution and the points of contact for the trial.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, reflecting a software/template update rather than a change to the study details or content.SummaryDifference0.1%

Stay in the know with updates to Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.